Clinical Pharmacokinetics of Paritaprevir.

about

Clinical Pharmacokinetics of Ombitasvir.Clinical Pharmacokinetics of Dasabuvir.Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

P2860

Q39147495-EC743F2A-8C40-4BD6-BC4C-DCCBC28F2B39 Q39160612-509DF101-6685-4A37-93C3-B58A39DF318F Q47567111-3188E34B-8881-41EE-B47E-E4202F524F78 Q48223561-6D492EDF-5F35-4DF0-833B-91B22C8FC234

P2860

Clinical Pharmacokinetics of Paritaprevir.

Item

http://www.wikidata.org/entity/Q39150134

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical Pharmacokinetics of Paritaprevir.

@en

Clinical Pharmacokinetics of Paritaprevir.

@nl

type

Item

label

Clinical Pharmacokinetics of Paritaprevir.

@en

Clinical Pharmacokinetics of Paritaprevir.

@nl

prefLabel

Clinical Pharmacokinetics of Paritaprevir.

@en

Clinical Pharmacokinetics of Paritaprevir.

@nl

P1476

Clinical Pharmacokinetics of Paritaprevir.

@en

P2093

Akshanth R Polepally

http://www.w3.org/2001/XMLSchema#string

Amit Khatri

http://www.w3.org/2001/XMLSchema#string

Rajeev M Menon

http://www.w3.org/2001/XMLSchema#string

Sandeep Dutta

http://www.w3.org/2001/XMLSchema#string

Walid M Awni

http://www.w3.org/2001/XMLSchema#string

P2860

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis

Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir

Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.

Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir

P2888

s40262-017-0520-x

P31

scholarly article

P356

10.1007/S40262-017-0520-X

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28236252

http://www.w3.org/2001/XMLSchema#string

Clinical Pharmacokinetics of Paritaprevir.

about

P2860

P2860

Clinical Pharmacokinetics of Paritaprevir.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698